Current stage -Stage II Posts on Medivizor
Navigation Menu

Current stage -Stage II Posts on Medivizor

Long term results discussing radiotherapy and hormone therapy treatments for patients with prostate cancer

Posted by on Dec 16, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...

Read More

Comparing robot-assisted laparoscopic prostate surgery versus open prostate surgery

Posted by on Dec 11, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to compare traditional open surgery and robotic surgery to treat prostate cancer in terms of side effects. It found that there was no difference in side-effects like sexual function or urinary problems between the two surgeries. Some background Prostate surgery is a treatment option for prostate cancer. This surgery...

Read More

Is conventional or hypofractionated radiation therapy better for the treatment of prostate cancer?

Posted by on Nov 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study compared two different types of radiation therapy after prostate surgery for prostate cancer, hypofractionated postprostatectomy radiation therapy (hypoPORT) and conventional postprostatectomy radiation therapy (coPORT). Results showed that hypoPORT may be effective in prostate cancer control and with similar side effects as...

Read More

Evaluating long-term outcomes of stereotactic body radiation therapy for low- and medium-risk prostate cancer

Posted by on Nov 13, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of stereotactic body radiation therapy (SBRT) as a treatment for prostate cancer. This study found that SBRT is a safe and effective option for low and medium risk prostate cancer. Some background Stereotactic body radiotherapy (SBRT) is a treatment option for...

Read More

Guidelines for hypofractionated radiation therapy for localized prostate cancer

Posted by on Nov 10, 2018 in Prostate cancer | 0 comments

In a nutshell This study reviewed the current recommendations for treatment doses of radiation therapy for different stages of prostate cancer.  Some background Hypo-fractionated radiation therapy (HFRT) for early-stage prostate cancer is a safe and effective treatment option. It involves a shorter course of treatment with larger doses...

Read More

2018 recommendations for the treatment of localized prostate cancer: Part II

Posted by on Sep 25, 2018 in Prostate cancer | 0 comments

In a nutshell This article reviewed treatment guidelines that have been recommended for patients with early-stage prostate cancer. Some background This analysis of existing treatment guidelines was done by the leading experts in prostate cancer research. They have made recommendations on the treatment of early-stage prostate cancer.  Methods...

Read More

Are higher doses of radiation in less time better than conventional radiotherapy for prostate cancer?

Posted by on Sep 1, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate whether dose-escalated hypo-fractionated (higher doses in less time) radiation therapy would lead to better overall survival or less chance of cancer recurrence than the conventional method. They found that there is superior cancer control associated with dose-escalated hypo-fractionated radiation therapy for...

Read More

Biochemical relapse-free survival outcomes for intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB)

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell This study examined rates of biochemical relapse after using intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB) in men with low and intermediate stage prostate cancer. This study found that rates of biochemical relapse were low after treatment.  Some background...

Read More